Salute e Benessere
Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Beyond therapeutics, diagnostics are experiencing a paradigm shift. A multicenter trial using revealed that patients achieving imaging-negative status post-transplant had progression-free survival of in those with residual disease. In addition, a novel liquid biopsy platform, , detected circulating tumor cells in of study participants, paving the way for non-invasive monitoring and potentially reducing reliance on traditional bone marrow biopsies.
The next-generation therapies market spans multiple drug classes, each contributing uniquely to improved outcomes and durable responses. such as , , , and continue to dominate frontline and maintenance regimens. including and remain foundational agents, while emerging such as iberdomide and mezigdomide promise deeper immune modulation. like , , and sustain relevance in multi-line therapy settings, supported by recent formulation advancements. such as , , , and are driving the next wave of targeted immune engagement. , including and , continue to deliver unprecedented remission rates for patients with heavily pretreated disease, while like have re-entered the U.S. market in 2024 following updated trial results demonstrating improved benefit–risk profiles.
In August 2024 , launched in Japan , expanding dosage flexibility for maintenance therapy in multiple myeloma. In August 2023 , received , a first-in-class bispecific antibody targeting GPRC5D for RRMM patients after four or more prior lines of therapy. These milestones emphasize the global momentum toward precision-engineered, immune-based therapies that extend survival while minimizing treatment toxicity.
The next decade promises significant transformation in the MM treatment paradigm.
"The evolving myeloma landscape in 2025 signals a shift from generalized therapy toward precision-driven, adaptive care," said . "Bispecific antibodies and CAR-T therapies are redefining treatment expectations, while novel imaging and liquid biopsy tools like SWIFT-seq are making disease monitoring less invasive and more informative."
The next-generation multiple myeloma market is segmented into , and .
The remains the largest market for next-generation multiple myeloma therapeutics, accounting for .
Japan's multiple myeloma market reached and is projected to hit , growing at .
Major companies shaping the next-generation multiple myeloma market include .
Collectively, the top five companies hold , supported by deep oncology pipelines, patient-access initiatives, and strategic co-development alliances.
(
is a global business intelligence and consulting firm headquartered in
Hyderabad, India . DataM delivers actionable insights across 15+ industry verticals, offering syndicated reports, customized consulting, and competitive intelligence solutions. The firm's oncology market coverage spans hematologic malignancies, solid tumors, and cell & gene therapies, providing deep-dive data on clinical pipelines, regulatory landscapes, pricing, and market access strategies.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/next-generation-multiple-myeloma-therapies-market-to-reach-usd-37-07-billion-by-2033--driven-by-accelerated-immunotherapy-approvals-and-precision-medicine-advances--datam-intelligence-302603937.html